Accuray (NASDAQ:ARAY) Announces Earnings Results

Accuray (NASDAQ:ARAY) released its quarterly earnings data on Wednesday. The medical equipment provider reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.03, Zacks reports. Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%.

Accuray Stock Up 6.9 %

NASDAQ:ARAY traded up $0.16 during trading hours on Wednesday, hitting $2.49. 1,593,060 shares of the company traded hands, compared to its average volume of 671,932. Accuray has a one year low of $1.40 and a one year high of $2.95. The company has a quick ratio of 0.87, a current ratio of 1.63 and a debt-to-equity ratio of 3.59. The company has a market cap of $250.41 million, a PE ratio of -14.65 and a beta of 1.51. The firm’s 50-day simple moving average is $2.09 and its 200-day simple moving average is $1.96.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.